ArticleNature communications2026
Lipopolysaccharide hydrolysis-targeting nano-chimeras detoxify endotoxin through specific adsorption and efficient degradation.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The two faces of mitochondrial CaJournal of physiology and biochemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipopolysaccharide (LPS), a potent immunogenic component of the outer membrane of Gram-negative bacteria, triggers severe inflammation and organ failure even at nanomolar concentrations. However, neutralizing LPS in vivo remains challenging due to the high abundance of other biomolecules in biological fluids, which interfere with LPS detoxification. Brassicaceae species produce a transmembrane protein termed lipooligosaccharide-specific reduced elicitation (LORE) that specifically recognizes and binds LPS. Here, we prepare plant-derived nanovesicles naturally presenting LORE on their surface and integrate them with cerium-based nanozymes exhibiting LPS hydrolysis activity. We show that these hybrid nanostructures (Atv@Ce) neutralize LPS through two coordinated mechanisms: LORE captures LPS specifically, while nanozymes chemically degrade the phosphate groups and glycosidic bonds in the lipid A moiety. This dual strategy effectively attenuates both local and systemic inflammation, offering a biocompatible detoxification strategy with translational potential. Our work provides an insight into nanomaterial-mediated detoxification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.